Perludil Algestone Estradiol 1 AMP INJECTION 1mg-Collins
Perludil is an injectable contraceptive that is administered intramuscularly once a month. It consists of two main assets: a progestin (acetophenide algestone) and an estrogen (estradiol enanthate).
The main mode of action is in the contraceptive progestogen agent, which produces a anovulatory effect by inhibiting the secretion of pituitary gonadotropins. Estrogen ensures cyclic endometrial development and predictable bleeding patterns are generally similar to those that occur naturally in menstruation.
PRECAUTIONS: Before treatment and every year for this, it is recommended to perform the medical examination of the drug users, including complete gynecological Pap.
Smoking increases the risk of cardiovascular side effects. The total risk increases with patient age, especially after age 35. It is highly recommended that women who start a hormonal contraceptive therapy of any kind to refrain from smoking.
Perlutal ® has a transient inhibitory effect on ovulation, which does not lead to sterility. However, this must be taken into account, as is the case with other hormonal contraceptives. The Natural ovarian cycle can be interrupted two or three months after stopping treatment.
In the following cases, the theoretical or proven risks generally outweigh the benefits of using Perlutal ® (in these cases the use of the drug requires careful clinical judgment, taking into account the severity of the condition and the availability, feasibility and acceptability of alternative contraceptive methods and careful monitoring):
• Smoking regulars (> 20 cigarettes / day), age> 35.
• Breastfeeding (6 weeks-6 months postpartum).
• <21 days postpartum (non-lactating).
• History of breast cancer.
• Unexplained vaginal bleeding.
• History of hypertension or blood pressure 160-180/100-110.
• Hyperlipidemias known.
• Use of certain antibiotics or anticonvulsants (see Drug Interactions and other gender).
• Liver tumors (benign).
use during pregnancy or breastfeeding. No use if suspected pregnancy. The combined administration of injectable contraceptives during lactation can cause reduction quantitative composition of breast milk. Regarding postpartum, blood coagulation and fibrinolysis are essentially normalized after 3 weeks of this, PERLUDIL ® can be used normally, so you should stop feeding the child from the womb.
ADVERSE REACTIONS: Especially at the start of treatment is likely that some women warn changes in menstrual bleeding patterns (shortening cycle, spotting or bleeding-do irregular, transient amenorrhea, dysmenorrhea, breast tenderness, abdominal pain, nausea, vomiting , headache, fluid retention and electrolyte changes in transient and subclinical hepatic excretion tests, weight gain and changes in libido).
As with any other estrogen and prostágeno, the following adverse reactions have been reported rarely with PERLUDIL ®: dizziness, nervousness, depression, hot flashes, acne or skin reactions such as itching, hearing and visual disturbances.
PRESENTATION: Box with a vial with 1 ml. Box prefilled syringe with 1 1 ml sterile needle.
RECOMMENDED STORAGE: Store at room temperature not exceeding 30 ° C.
ï‚· Drug Name: perludil
comparable to: Perlutal
ï‚· Active ingredients: algestone / estradiol
ï‚· concentration: 150mg/10mg
ï‚· presentation: Injectable Solution
ï‚· box: 1 vial with 1 ml
ï‚· Laboratory: Collins
ï‚· Made in: Mexico